Nemvaleukin
Phase 3Protein / enzyme
Nemvaleukin is one of 57 biologic programs targeting Ovarian Cancer. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Votrient
NovartisPhase 3
Trodelvy
GileadPhase 3
Aromasin
PfizerPhase 3
Rina-S
GenmabPhase 3
Single Dose of
Boehringer IngelheimPhase 3
Azenosertib
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 3
JSKN003
JJiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
GSK5733584
GSKPhase 3
Doxorubicin HCL Liposome
AAccelerated Community Oncology Research Network
Phase 3
In Vitro Sensitivity-Directed Chemotherapy
CChildren's Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tumor Microenvironment1 trial
Head and Neck Cancer1 trial
Mucosal Melanoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nemvaleukin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company
- MMural Oncology, Inc